House subcommittee members questioned why Emergent BioSoultions awarded bonuses to executives despite quality problems than hindered production of Johnson & Johnson's COVID-19 vaccine.
The blocked shipment of AstraZeneca COVID-19 vaccines was the first intervention by the EU since the bloc approved rules that could restrict vaccine exports to non-member nations.
